Format

Send to

Choose Destination
J Clin Aesthet Dermatol. 2014 May;7(5):15-8.

Efficacy and safety of a low molecular weight hyaluronic Acid topical gel in the treatment of facial seborrheic dermatitis final report.

Author information

1
Dermatology and Laser Center of Charleston, Clinical Research Department, Charleston, South Carolina.

Abstract

OBJECTIVE:

Hyaluronic acid sodium salt gel 0.2% is a topical device effective in reducing skin inflammation. Facial seborrheic dermatitis, characterized by erythema and or flaking/scaling in areas of high sebaceous activity, affects up to five percent of the United States population. Despite ongoing study, the cause of the condition is yet unknown, but has been associated with yeast colonization and resultant immune derived inflammation. First-line management typically is with keratolytics, topical steroids, and topical antifungals as well as the targeted immunosuppressant agents pimecrolimus and tacrolimus. The objective of this study was to evaluate the efficacy and safety of a novel topical antiinflammatory containing low molecular weight hyaluronic acid.

DESIGN AND SETTING:

Prospective, observational, non-blinded safety and efficacy study in an outpatient setting.

PARTICIPANTS:

Individuals 18 to 75 years of age with facial seborrheic dermatitis.

MEASUREMENTS:

Outcome measures included scale, erythema, pruritus, and the provider global assessment, all measured on a five-point scale. Subjects were assessed at baseline, Week 2, Week 4, and Week 8.

RESULTS:

Final data with 13 of 17 subjects are presented. Hyaluronic acid sodium salt gel 0.2% was shown through visual grading assessments to improve the provider global assessment by 65.48 percent from baseline to Week 4. Reductions in scale, erythema, and pruritus were 76.9, 64.3, and 50 percent, respectively, at Week 4. At Week 8, the provider global assessment was improved from baseline in 92.3 percent of subjects.

CONCLUSION:

Treatment with topical low molecular weight hyaluronic acid resulted in improvement in the measured endpoints. Final data reveal continued improvement from that seen in the interim data shown previously. Topical low molecular weight hyaluronic acid is another option that may be considered for the treatment of facial seborrheic dermatitis in the adult population. Compliance and tolerance were excellent.

PMID:
24847403
PMCID:
PMC4025514

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center